Fact CheckerSign in

NCT06820567Not yet recruitingPhase 3

Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD

English Title of Research Project: Effects of Dapagliflozin on Inflammatory Markers, Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD

Source: ClinicalTrials.gov · Last updated 11 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

the effect of Dapagliflozin on erythropoiesis, iron metabolism and inflammatory markers in CKD with Type 2 DM-Compare between effect of placebo and dapagliflozin on erythropoiesis, iron metabolism and inflammation markers in CKD with Type 2 DM.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
210 (estimated)
First submitted
6 Feb 2025
Start date
1 Mar 2025
Primary completion date
1 Mar 2026
Lead sponsor
Assiut University
NCT number
NCT06820567

What you commit to

  • Study type: Interventional · Phase 3
  • Planned participants: 210
  • From 1 Mar 2025 to the primary completion date, 1 Mar 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • type 1 diabetes, non-diabetes kidney disease and patient with HB \< 9

Who the study is looking for

  • Eligible participants were aged \>18 years and diagnosed with Type 2 diabetes participants we required to have urinary albumin-creatinine ratio (UACR ) of 30\_3500 mg /g ,eGFR of 20\_ 80 ml/min/ 1.73 m , and HbA1c of 7.0 \_ 11.0 % at screening

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.